公开(公告)号：US20220218726A1

公开(公告)日：2022-07-14

申请号：US17416883

申请日：2019-12-19

Applicant: Korea Basic Science Institute

Inventor： Gun Hwa Kim ,  Min Ji Lee ,  Koon Soon Kim ,  Hyo Kyun Chung ,  Ji Hoon Lee ,  Se Jin Jung ,  Da Rong Kim

IPC: A61K31/635

Abstract: The present invention relates to a composition comprising a CYP4A-inhibiting compound as an active ingredient for preventing or treating metabolic diseases, more specifically to a composition comprising the compound expressed by chemical formula 1 of the present invention or pharmaceutically acceptable salt thereof as an active ingredient for preventing, ameliorating or treating metabolic diseases.

公开(公告)号：US10166223B2

公开(公告)日：2019-01-01

申请号：US15984258

申请日：2018-05-18

Applicant: KOREA BASIC SCIENCE INSTITUTE

Inventor： Gun Hwa Kim ,  Joo Hyun Park ,  Min Ji Lee

IPC: A61K31/4545 ,  A61K31/538 ,  A61P1/16 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.

公开(公告)号：US20180333404A1

公开(公告)日：2018-11-22

申请号：US15984258

申请日：2018-05-18

Applicant: KOREA BASIC SCIENCE INSTITUTE

Inventor： Gun Hwa Kim ,  Joo Hyun Park ,  Min Ji Lee

IPC: A61K31/4545 ,  A61P3/10 ,  A61P1/16 ,  A61K31/538

CPC classification number: A61K31/4545 ,  A61K31/538 ,  A61P1/16 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.